stoxline Quote Chart Rank Option Currency Glossary
  
DiaMedica Therapeutics Inc. (DMAC)
2.77  0.12 (4.53%)    03-28 16:00
Open: 2.73
High: 2.81
Volume: 20,669
  
Pre. Close: 2.65
Low: 2.73
Market Cap: 105(M)
Technical analysis
2024-03-28 4:50:51 PM
Short term     
Mid term     
Targets 6-month :  3.49 1-year :  3.9
Resists First :  2.99 Second :  3.33
Pivot price 2.82
Supports First :  2.44 Second :  2.03
MAs MA(5) :  2.71 MA(20) :  2.89
MA(100) :  2.79 MA(250) :  2.74
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  30.3 D(3) :  29.3
RSI RSI(14): 45.3
52-week High :  4.75 Low :  1.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DMAC ] has closed above bottom band by 38.1%. Bollinger Bands are 0.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.81 - 2.83 2.83 - 2.84
Low: 2.7 - 2.71 2.71 - 2.73
Close: 2.75 - 2.77 2.77 - 2.79
Company Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Headline News

Mon, 25 Mar 2024
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript - Yahoo Finance

Sat, 23 Mar 2024
DiaMedica Therapeutics (NASDAQ:DMAC) PT Lowered to $8.00 - Defense World

Fri, 22 Mar 2024
DiaMedica Therapeutics (NASDAQ:DMAC) Receives “Outperform” Rating from Oppenheimer - Defense World

Fri, 22 Mar 2024
DiaMedica Therapeutics (NASDAQ:DMAC) Rating Reiterated by Oppenheimer - MarketBeat

Thu, 21 Mar 2024
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability - Yahoo Finance

Tue, 19 Mar 2024
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 38 (M)
Shares Float 24 (M)
Held by Insiders 26.7 (%)
Held by Institutions 22 (%)
Shares Short 196 (K)
Shares Short P.Month 196 (K)
Stock Financials
EPS -0.61
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.35
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30.1 %
Return on Equity (ttm) -46.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -19 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -4.62
PEG Ratio -0.2
Price to Book value 2.05
Price to Sales 0
Price to Cash Flow -5.62
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android